RedHill Biopharma Authorized to Test RHB-104 for Crohn’s Disease in Australia and New Zealand

RedHill Biopharma Authorized to Test RHB-104 for Crohn’s Disease in Australia and New Zealand
Israel-based RedHill Biopharma Ltd. recently disclosed it has been granted authorization to begin enrolling patients in Australia and New Zealand for a Phase III clinical trial designed to test RHB-104 as a potential treatment for Crohn’s disease. The company has already commenced screening of study participants in New Zealand. RHB-104 is an innovative orally available, combined antibiotic that

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *